Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 01, 2023 07:00 ET
|
Neumora Therapeutics, Inc.
Navacaprant Phase 3 KOASTAL program in major depressive disorder on track; planned initiation of Phase 2 bipolar depression trial in 1H24 Progressing NMRA-511 and NMRA-266 toward near-term clinical...
Neumora Therapeutics to Participate in Upcoming Conferences in November
October 30, 2023 07:00 ET
|
Neumora Therapeutics, Inc.
WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...
Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
October 10, 2023 07:00 ET
|
Neumora Therapeutics, Inc.
WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...
Neumora Therapeutics Announces Pricing of Initial Public Offering
September 14, 2023 20:49 ET
|
Neumora Therapeutics, Inc.
WATERTOWN, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the...